Corelation Between Matrix Metalloproteinase-9 (MMP-9) And Troponin-I (cTn-I) in ST- Elevation Myocardial Infarction (STEMI) and Non ST-Elevation Acute Coronary Syndrome (NSTEACS)
Abstract
Background: Acute coronary syndrome (ACS) is due to plaque rupture or erosion. Plaque rupture or erosion occurs because of the extra-cellular matrix destruction by an MMP (matrix metalloproteinase). Troponin I (cTn-I) is a biomarker that will increase in ACS with myocardial necrosis.Objective: To determine levels of MMP-9 difference between STEMI and NSTEACS and the relationship between levels of MMP-9 and cTn-I levels between the two groups.
Methods: The sample examination performed in 80 patients with ACS (39 STEMI and 41 with NSTE-ACS) prior to the act of intravenous thrombolysis or coronary intervention.Analysis of MMP-9 levels relationship and cTn-I using Spearman test, and analysis of the cut-off relationship MMP-9 in the STEMI and NSTEACS groups were tested by Chi square.
Results: Group STEMI had higher levels of MMP-9 and significantly higher compared with NSTE-ACS group (p = 0.002). Spearman correlation test showed a significant and positive correlation between MMP-9 and troponin-I between the two groups (p = 0.003 and r = 0.33).
Conclusion: Increased levels of MMP-9 were significantly higher in STEMI compared with NSTE-ACS and its association with elevated levels of tro-ponin-I, provide information about the role of MMP-9 against the severity of heart muscle damage that occurred.
Downloads
Download data is not yet available.
References
Agewall S. Matrix metalloproteinases and cardiovascular disease. Eur Heart J. 2006; 27: 121–122.
Newby AC. Dual Role of Matrik metalloproteinases (Matrikins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005; 85:1-31.
Collinson PO, Gaze DC. Biomarkers of cardiovascular damage and dysfunction. An Overview, Heart, Lung and Circulation. 2007;16:S71–S82.
Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocar-dial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007; 28:2525–38.
Braunwald E, Antman EM, Beasley JW. ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina. 2002 Available from: URL: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf.
Eckart REDO, Uyehara CFT, Shry EA, Furgerson JL, Krasuski RA. Matrix metalloproteinases in patient with myocardial in-farction and percutaneous revascularization. J Interven Cardiol. 2004; 17: 27-31.
Wright JL, Tai H, Wang R, Wang X, Churg A. Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-alpha signaling. Am J Physiol Lung Cell Mol Physiol. 2007: 292: L125–33.
Sillanaukee P, Kalela A, Seppa K, Hoyhtya M, Nikkari ST. Matrix metalloproteinase-9 is elevated in serum of alcohol abusers. Eur J Clin Invest. 2002; 32: 225–9.
Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, Mac-Fadyen RJ, et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hyper-tens. 2004; 17: 764–9.
Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol. 2005; 25: 372.
Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation. 2004;109: 2850–6.
Manginas A, Bei E, Chaidaroglou A, et al. Peripheral levels of matrix metalloproteinase-9, Interleukin-6, and C-Reactive protein are elevated in patients with acute coronary syndromes: Correlations with serum Troponin I. Clin Cardiol. 2005: 28; 182–6.
Tan J, HATS Q, Gao J, Fan ZX, Clinical implications of elevated serum Interleukin-6, Soluble CD40 Ligand, Metalloprotei-nase-9, and Tissue Inhibitor of Metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol. 2008; 31: 413–8.
Shu J, Ren N, Du JB, Zhang M, Cong HL, Huang TG. In-creased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome. Scandinavian Cardiovasc J. 2007: 41: 149-54.
Fukuda D, Shimada K, Tanaka A, et al. Comparison of Levels of Serum Matrix Metalloproteinase-9 in Patients With Acute Myocardial Infarction Versus Unstable Angina Pectoris Versus Stable Angina Pectoris. Am J Cardiol. 2006; 97:175–80.
Apple FS, Wu AHB, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clinical Chemistry. 2005:51; 810–24.
Higo S, Uematsu M, Yamagishi M, et al. Elevation of plasma matrix metalloproteinase-9 in the culprit coronary artery in patients with acute myocardial infarction clinical evidence from distal protection. Circulation.2005;69:1180-5.
Kaden JJ, Dempfle CE, Sueselbeck T, Brueckmann M, Poerner TC, Haghi D, Haase KK, Borggrefe M. Time-dependent changes in the plasma concentration of matrix metalloproteinase-9 after acute myocardial infarction. Cardiology. 2003; 99:140–4.
Newby AC. Dual Role of Matrik metalloproteinases (Matrikins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005; 85:1-31.
Collinson PO, Gaze DC. Biomarkers of cardiovascular damage and dysfunction. An Overview, Heart, Lung and Circulation. 2007;16:S71–S82.
Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocar-dial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007; 28:2525–38.
Braunwald E, Antman EM, Beasley JW. ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina. 2002 Available from: URL: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf.
Eckart REDO, Uyehara CFT, Shry EA, Furgerson JL, Krasuski RA. Matrix metalloproteinases in patient with myocardial in-farction and percutaneous revascularization. J Interven Cardiol. 2004; 17: 27-31.
Wright JL, Tai H, Wang R, Wang X, Churg A. Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-alpha signaling. Am J Physiol Lung Cell Mol Physiol. 2007: 292: L125–33.
Sillanaukee P, Kalela A, Seppa K, Hoyhtya M, Nikkari ST. Matrix metalloproteinase-9 is elevated in serum of alcohol abusers. Eur J Clin Invest. 2002; 32: 225–9.
Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, Mac-Fadyen RJ, et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hyper-tens. 2004; 17: 764–9.
Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol. 2005; 25: 372.
Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation. 2004;109: 2850–6.
Manginas A, Bei E, Chaidaroglou A, et al. Peripheral levels of matrix metalloproteinase-9, Interleukin-6, and C-Reactive protein are elevated in patients with acute coronary syndromes: Correlations with serum Troponin I. Clin Cardiol. 2005: 28; 182–6.
Tan J, HATS Q, Gao J, Fan ZX, Clinical implications of elevated serum Interleukin-6, Soluble CD40 Ligand, Metalloprotei-nase-9, and Tissue Inhibitor of Metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol. 2008; 31: 413–8.
Shu J, Ren N, Du JB, Zhang M, Cong HL, Huang TG. In-creased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome. Scandinavian Cardiovasc J. 2007: 41: 149-54.
Fukuda D, Shimada K, Tanaka A, et al. Comparison of Levels of Serum Matrix Metalloproteinase-9 in Patients With Acute Myocardial Infarction Versus Unstable Angina Pectoris Versus Stable Angina Pectoris. Am J Cardiol. 2006; 97:175–80.
Apple FS, Wu AHB, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clinical Chemistry. 2005:51; 810–24.
Higo S, Uematsu M, Yamagishi M, et al. Elevation of plasma matrix metalloproteinase-9 in the culprit coronary artery in patients with acute myocardial infarction clinical evidence from distal protection. Circulation.2005;69:1180-5.
Kaden JJ, Dempfle CE, Sueselbeck T, Brueckmann M, Poerner TC, Haghi D, Haase KK, Borggrefe M. Time-dependent changes in the plasma concentration of matrix metalloproteinase-9 after acute myocardial infarction. Cardiology. 2003; 99:140–4.
Views & Downloads
Abstract views: 3406
PDF (Bahasa Indonesia) downloads: 4082
PDF (Bahasa Indonesia) downloads: 4082
How to Cite
Setianto, B., Astuti, I., Irawan, B., & Mubarika, S. (1). Corelation Between Matrix Metalloproteinase-9 (MMP-9) And Troponin-I (cTn-I) in ST- Elevation Myocardial Infarction (STEMI) and Non ST-Elevation Acute Coronary Syndrome (NSTEACS). Indonesian Journal of Cardiology, 32(1), 4-11. https://doi.org/10.30701/ijc.v32i1.114
Section
Clinical Research
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
